Literature DB >> 11980523

Pathogenesis of high-altitude pulmonary edema: inflammation is not an etiologic factor.

Erik R Swenson1, Marco Maggiorini, Stephen Mongovin, J Simon R Gibbs, Ilona Greve, Heimo Mairbäurl, Peter Bärtsch.   

Abstract

CONTEXT: The pathogenesis of high-altitude pulmonary edema (HAPE) is considered an altered permeability of the alveolar-capillary barrier secondary to intense pulmonary vasoconstriction and high capillary pressure, but previous bronchoalveolar lavage (BAL) findings in well-established HAPE are also consistent with inflammatory etiologic characteristics.
OBJECTIVES: To determine whether inflammation is a primary event in HAPE and to define the temporal sequence of events in HAPE. DESIGN, SETTING, AND PARTICIPANTS: Case study from July through August 1999 of 10 subjects with susceptibility to HAPE and 6 subjects resistant to HAPE, all of whom are nonprofessional alpinists with previous mountaineering experience above 3000 m. MAIN OUTCOME MEASURES: Pulmonary artery pressure measurements and BAL findings at low altitude (490 m) and shortly before or at the onset of HAPE at an altitude of 4559 m.
RESULTS: Subjects who were HAPE susceptible had higher mean (SD) pulmonary artery systolic blood pressures at 4559 m compared with HAPE-resistant subjects (66 vs 37 mm Hg; P =.004). Despite development of HAPE in the majority of HAPE-susceptible subjects, there were no differences in BAL fluid total leukocyte counts between resistant and susceptible subjects or between counts taken at low and high altitudes. Subjects who developed HAPE had BAL fluid with high concentrations of plasma-derived proteins and erythrocytes, but there was no increase in plasma concentrations of surfactant protein A and Clara cell protein. The chest radiograph score was 12.7 for the 3 HAPE-susceptible subjects who developed HAPE before BAL was performed; they were lavaged within 3 to 5 hours. The remainder of the HAPE-susceptible group was lavaged before edema was apparent on radiographs. However, 6 subjects from the HAPE-susceptible group who developed HAPE on the following day had a score on bronchoscopy of 1.5, which increased to 4.6, reflective of mild pulmonary edema. In HAPE cases, there were no elevations in a number of proinflammatory cytokines and eicosanoid and nitric oxide metabolites.
CONCLUSIONS: Early HAPE is characterized by high pulmonary artery pressures that lead to a protein-rich and mildly hemorrhagic edema, with normal levels of leukocytes, cytokines, and eicosanoids. HAPE is a form of hydrostatic pulmonary edema with altered alveolar-capillary permeability.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11980523     DOI: 10.1001/jama.287.17.2228

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  65 in total

1.  Prevention and Treatment of High-altitude Illness in Travelers.

Authors:  David R. Murdoch
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

2.  Going to altitude? Bring your vitamins!

Authors:  Carsten Lundby
Journal:  J Physiol       Date:  2010-12-01       Impact factor: 5.182

Review 3.  Nitric oxide in adaptation to altitude.

Authors:  Cynthia M Beall; Daniel Laskowski; Serpil C Erzurum
Journal:  Free Radic Biol Med       Date:  2012-01-20       Impact factor: 7.376

Review 4.  Cellular stress failure in ventilator-injured lungs.

Authors:  Nicholas E Vlahakis; Rolf D Hubmayr
Journal:  Am J Respir Crit Care Med       Date:  2005-02-01       Impact factor: 21.405

5.  The effect of 18 h of simulated high altitude on left ventricular function.

Authors:  Jesper Kjaergaard; Eric M Snyder; Christian Hassager; Thomas P Olson; Jae K Oh; Bruce D Johnson
Journal:  Eur J Appl Physiol       Date:  2006-09-21       Impact factor: 3.078

6.  High-altitude pulmonary hypertension is associated with a free radical-mediated reduction in pulmonary nitric oxide bioavailability.

Authors:  Damian M Bailey; Christoph Dehnert; Andrew M Luks; Elmar Menold; Christian Castell; Guido Schendler; Vitalie Faoro; Mariusz Gutowski; Kevin A Evans; Sarah Taudorf; Philip E James; J McEneny; Ian S Young; Erik R Swenson; Heimo Mairbäurl; Peter Bärtsch; Marc M Berger
Journal:  J Physiol       Date:  2010-09-27       Impact factor: 5.182

7.  Lung disease at high altitude.

Authors:  Joshua O Stream; Andrew M Luks; Colin K Grissom
Journal:  Expert Rev Respir Med       Date:  2009-12       Impact factor: 3.772

8.  The Effects of Portulaca oleracea on Hypoxia-Induced Pulmonary Edema in Mice.

Authors:  Tan Yue; Wen Xiaosa; Qi Ruirui; Shi Wencai; Xin Hailiang; Li Min
Journal:  High Alt Med Biol       Date:  2015-03-11       Impact factor: 1.981

9.  Hydrostatic mechanisms may contribute to the pathogenesis of human re-expansion pulmonary edema.

Authors:  Richard D Sue; Michael A Matthay; Lorraine B Ware
Journal:  Intensive Care Med       Date:  2004-07-17       Impact factor: 17.440

10.  Management of high altitude pulmonary edema in the Himalaya: a review of 56 cases presenting at Pheriche medical aid post (4240 m).

Authors:  Barbara E Jones; Suzy Stokes; Suzi McKenzie; Eric Nilles; Gregory J Stoddard
Journal:  Wilderness Environ Med       Date:  2012-10-10       Impact factor: 1.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.